Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Cosmi

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Cardiac Failure|December 21, 2021
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE TrialJob A J Verdonschot, JoÃo Pedro Ferreira, Anne Pizard, et al.
European Journal of Heart Failure|November 29, 2021
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trialSusana Ravassa, Begoña López, João Pedro Ferreira, et al.
European Journal of Heart Failure|June 15, 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trialMasatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, et al.
ESC Heart Failure|September 6, 2022
Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trialLuca Monzo, João Pedro Ferreira, John G F Cleland, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trialJoão Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
European Journal of Heart Failure|May 13, 2016
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimensMichele Senni, John J V McMurray, Rolf Wachter, et al.
European Journal of Heart Failure|March 1, 2018
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetesFranco Cosmi, Li Shen, Michela Magnoli, et al.
JACC. Heart Failure|February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HFJoão Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
European Heart Journal|November 20, 2020
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trialJohn G F Cleland, João Pedro Ferreira, Beatrice Mariottoni, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Cardiac Failure|December 21, 2021
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE TrialJob A J Verdonschot, JoÃo Pedro Ferreira, Anne Pizard, et al.
European Journal of Heart Failure|November 29, 2021
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trialSusana Ravassa, Begoña López, João Pedro Ferreira, et al.
European Journal of Heart Failure|June 15, 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trialMasatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, et al.
ESC Heart Failure|September 6, 2022
Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trialLuca Monzo, João Pedro Ferreira, John G F Cleland, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trialJoão Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
European Journal of Heart Failure|May 13, 2016
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimensMichele Senni, John J V McMurray, Rolf Wachter, et al.
European Journal of Heart Failure|March 1, 2018
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetesFranco Cosmi, Li Shen, Michela Magnoli, et al.
JACC. Heart Failure|February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HFJoão Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
European Heart Journal|November 20, 2020
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trialJohn G F Cleland, João Pedro Ferreira, Beatrice Mariottoni, et al.
Pageof 5